FINWIRES · TerminalLIVE
FINWIRES

BP Confirms Preliminary Offshore Exploration Agreement With Venezuela

By

-- BP (BP.L) entered into a memorandum of understanding with the Bolivarian Republic of Venezuela to establish "potential areas for co‑operation in material offshore gas and future exploration," according to a statement sent toon Thursday.

Venezuela's Acting President Delcy Rodríguez announced in a Wednesday signing event its offshore natural gas exploration deal with the British oil major, which covers the Deltana Platform, an oil and natural gas reservoir in the nation's eastern waters, according to a same-day report from Bloomberg News.

BP Executive Vice President William Lin also said the company plans to launch a permanent regional office in Caracas, Venezuela.

Related Articles

Treasury

Bank of Canada Keeps Neutral Rate Unchanged and Looks Likely to Stay on Hold This Year, Says BMO

The Bank of Canada is potentially on a long hiatus from policy rate changes, assuming growth and inflation evolve roughly in-line with current expectations, said Bank of Montreal (BMO).Consistent with that, the BoC on Wednesday left the assumed neutral range unchanged at 2.25%-to-3.25% in its annual April refresh, noted the bank.That leaves the current policy rate right at the low end of the presumed range.Holding the neutral rate down is the stall in population growth and the drag that it has had on labor force growth, stated BMO.Holding the neutral rate up is some improvement in productivity growth and firmness -- even a touch of upside -- in the United States neutral rates, which have an impact on Canada, according to the bank.All things considered, BMO is comfortable with its view that the BoC is on hold this year.

$$CXY
Asia

Zhangzhou Pientzehuang Pharmaceutical's Attributable Profit Slides 26% in Q1

Zhangzhou Pientzehuang Pharmaceutical's (SHA:600436) attributable profit fell 26% to 743.5 million yuan in the first quarter from 999.8 million yuan in the year-ago period, according to a Thursday filing with the Shanghai bourse.Earnings per share at the drug company decreased to 1.23 yuan from 1.66 yuan in the prior-year period.Operating revenue declined 13% year over year to 2.74 billion yuan from 3.14 billion yuan.

$SHA:600436
Research

CICC Starts Ongoal Technology at Outperform with 185 Yuan Price Target

$SHE:301662